Introduction {#Sec1}
============

Immune checkpoints are regulatory molecules of the immune system and play an important role in maintaining immune homeostasis and self-tolerance^[@CR1]^. The first immune checkpoints that were identified include cytotoxic T-lymphocyte protein-4 (CTLA-4) and programmed cell death protein-1 (PD-1)^[@CR2]^. CTLA-4 is expressed on the surface of T cells, binds to B7-1 (CD80) or B7-2 (CD86) molecules on antigen-presenting cells, and functions as a negative regulator of T cells^[@CR3]^. PD-1 also has a negative effect on T cell activity through interactions with its ligands, including programmed death ligand-1 (PD-L1) and programmed death ligand-2 (PD-L2)^[@CR4]^. Unlike CTLA-4, PD-1 is not only found on T cells but is also broadly expressed on many immunologic cells, including B cells and natural killer cells^[@CR5],[@CR6]^. In healthy individuals, the surface expression of both CTLA-4 and PD-1 is tightly and dynamically regulated^[@CR7],[@CR8]^.

During the development of cancer, malignant cells inhibit the immune response by activating immune checkpoints. Previous studies have shown that PD-L1 is expressed in a wide range of cancers^[@CR9]--[@CR11]^. In the tumor microenvironment, PD-L1 expressed by cancerous cells interacts with PD-1 on the surface of T cells to inhibit effector function of T cells. In addition, a number of studies have demonstrated that high tumor expression of PD-L1 is significantly correlated with poor prognosis of carcinoma^[@CR12],[@CR13]^. These studies suggest that there is a therapeutic effect of PD-1 signaling pathway blockade in cancer.

Recent clinical trials have revealed that several anti-PD-1 and anti-PD-L1 immune checkpoint inhibitors (ICIs) are effective in a variety of cancers, such as melanoma, non-small cell lung carcinoma, renal cell carcinoma, and head and neck cancer^[@CR14]--[@CR16]^. Additional clinical trials are currently underway to expand the indication for ICIs. To date, The U.S. Food and Drug Administration (FDA) has approved three anti-PD-1 antibodies, nivolumab, pembrolizumab, and cemiplimab, and three anti-PD-L1 inhibitors, atezolizumab, avelumab, and durvalumab, for the treatments of different types of cancer.

As the use of ICIs increases, the adverse events related to this class of drugs have become an important issue. ICIs have a different toxicity profile than conventional cytotoxic chemotherapy. The side effects associated with the increased activity of the immune system by ICIs, known as immune-related adverse events (irAEs), can affect multiple organs of the body including skin, gastrointestinal tract, endocrine system, liver, lung, nervous systems, and musculoskeletal systems. Studies have shown that up to 80% of patients receiving ICIs experience adverse events (AEs)^[@CR17]--[@CR20]^.

Although many reports related to irAEs have been recently published, few studies have investigated risk factors associated with irAEs. A systematic review and meta-analysis, for example, has shown distinct patterns of irAEs according to the ICI class (CTLA-4 or PD-1/PD-L1) or tumor type (melanoma or non-melanoma). However, in these studies, only the types of drugs were investigated for the risk factors of irAEs^[@CR21]--[@CR26]^. To our knowledge, data on additional factors that predict the occurrence of irAEs are lacking. Herein, by retrospective medical record review, we analyzed irAEs in patients treated with pembrolizumab at Samsung Medical Center, Seoul, Korea between June 2015 and December 2017, to identify risk factors associated with irAEs.

Patients and Methods {#Sec2}
====================

Patients {#Sec3}
--------

All patients aged 18 years and older who had received at least one dose of pembrolizumab at Samsung Medical Center, Seoul, Korea from June 2015 to December 2017 were included in this study. The exclusion criteria included patients who received pembrolizumab in combination with other ICIs or other therapeutic agents including conventional chemotherapeutic agents and targeted therapy, and patients who lacked follow up after one dose of pembrolizumab.

Collection of data {#Sec4}
------------------

Data from the time pembrolizumab was first prescribed until the time of switching medication, the time of death, or the end of the study period were collected through retrospective medical record review. At the time of starting pembrolizumab, demographic data including sex, age, body weight, height, BMI, cancer type, and laboratory test results were obtained. BMI was categorized into four groups according to the proposed classification in adult Asian population presented by World Health Organization; Underweight, BMI \< 18.5 kg/m^2^; normal, 18.5 kg/m^2^ ≤ BMI \< 23 kg/m^2^; overweight, 23 kg/m^2^ ≤ BMI \< 25 kg/m^2^; obese, BMI ≥25 kg/m^2^ ^[@CR27]^. A derived neutrophil to lymphocyte count (dNLR) was calculated using the formula: absolute neutrophil count/(white blood cell count -- absolute neutrophil count)^[@CR28]^. Collected data included details of pembrolizumab therapy (e.g., dose, cycle) and drug-related AEs and irAEs (e.g., occurrence, grade, type, treatment and progress). AEs were graded using the Common Terminology Criteria for Adverse Events v4.0. The grading of irAEs was determined by treating physicians (hematologists and oncologists). Patients suspected of having irAEs were reviewed through a chart review, and only those patients deemed highly likely to have irAEs were included in the study.

Statistical analysis {#Sec5}
--------------------

Student's t-test, chi-square, and linear by linear association test were used to compare baseline characteristics of patients with and without irAEs. We performed univariate and multivariate logistic regression analyses to identify variables associated with irAE development. All statistical analyses were conducted using SPSS, version 24 (SPSS Inc., Chicago, IL, USA). The present study protocol conformed to the ethical guidelines of the 1975 Declaration of Helsinki, as revised in 1983, and was approved by the Institutional Review Board of Samsung Medical Center. The need for informed consent was waived owing to the retrospective nature of the study.

Results {#Sec6}
=======

A total 391 patients were included in the study, of which 63.2% were male. The median age was 60 years (18--95 years), and the median follow-up time was 48 days (1--794 days). The primary malignancies included in the study were lung cancer, melanoma, lymphoma, and others (Table [1](#Tab1){ref-type="table"}). The median dose per cycle of pembrolizumab was 167 mg (100--240 mg), and the median number of cycles was 2 (1--36). Table [1](#Tab1){ref-type="table"} shows a comparison of baseline characteristics between patients who experienced irAEs and those who did not.Table 1Comparison of baseline characteristics between patients with and without immune-related adverse events\*.Patients with irAEs (n = 67)Patients without irAEs (n = 324)**Age, years**59 (52--66)60 (52--69)0.309**Sex, male**45 (67.2)202 (62.3)0.457**BMI, kg/m** ^**2**^23.5 (20.8--25.8)22.5 (20.2--24.5)0.040**BMI category** ^**†**^**0.211**Underweight4 (6.0)39 (12.0)Normal26 (38.8)146 (45.1)Overweight18 (26.9)74 (22.8)Obese19 (28.4)65 (20.1)**Cancer type0.091**Lung cancer32 (47.8)179 (55.2)Melanoma21 (31.3)53 (16.4)Lymphoma8 (11.9)45 (13.9)Gastric cancer1 (1.5)15 (4.6)Urothelial cancer2 (3.0)6 (1.9)Others3 (4.5)26 (8.0)**Pembrolizuamb therapy**Dose/cycle, mg133 (100--200)185.5 (100--200)0.708Number of cycles4 (2--8)2 (1--4)\<0.001Cumulative dose, mg600 (300--1200)400 (200--600)0.001**Baseline laboratory finding**WBC, cells/mm^3^6000 (4860--7710)7280 (5400--9865)0.012ANC, cells/mm^3^3680 (2600--5900)4700 (3160--7343)0.010dNLR2.16 (1.10--2.40)3.13 (1.40--3.60)0.005dNLR category**0.001**\<358 (86.6)216 (66.7)≥39 (13.4)108 (33.3)Eosinophil count, cells/mm^3^92 (21--210)99 (28--189)0.998Albumin, g/dL4.1 (3.8--4.4)4.0 (3.5--4.4)0.110^\*^Data are presented as median with interquartile range or number (%). irAEs, immune-related adverse events; BMI, body mass index; WBC, white blood cell count; ANC, absolute neutrophil count; dNLR, derived neutrophil/lymphocyte ratio.^†^BMI is categorized based on the proposed classification of weight by BMI in adult Asians^[@CR27]^.Underweight, BMI \< 18.5 kg/m^2^; normal, 18.5 ≤ BMI \< 23; overweight, 23 ≤ BMI \< 25; obese, BMI ≥ 25.

The incidence of any grade and grade 3 or higher AEs were 27.1% and 4.1% respectively. Sixty-seven patients experienced 88 irAEs; 14 of whom experienced 16 grade 3 or higher irAEs. Dermatological disorders were the most commonly reported irAEs followed by pneumonitis musculoskeletal disorders and endocrinopathies (Table [2](#Tab2){ref-type="table"}). Table [3](#Tab3){ref-type="table"} summarizes the serious irAEs, including pneumonitis. There were 4 deaths associated with irAEs, all of which were due to pneumonitis. The majority of patients who experienced severe irAEs were treated with steroids (Table [3](#Tab3){ref-type="table"}).Table 2Clinically significant immune-related adverse events\*.All gradeGrade ≥ 3Dermatologic49 (55.7)3 (3.4)    Pruritis24 (27.3)---    Rash23 (26.1)3 (3.4)    Vitiligo2 (2.3)---Musculoskeletal12 (13.6)2 (2.3)    Myalgia5 (5.7)---    Myositis1 (1.1)1 (1.1)    Myasthenia gravis1 (1.1)1 (1.1)    Arthralgia3 (3.4)---    Arthritis2 (2.3)---Pulmonary11 (12.5)9 (10.2)Endocrinopathy7 (8.0)---Gastrointestinal5 (5.7)1 (1.1)    Diarrhea4 (4.6)---    Enterocolitis1 (1.1)1 (1.1)Hepatic3 (3.4)1 (1.1)Dry mouth1 (1.1)---Total88 (100.0)16 (18.2)\*All data are presented as number of cases (%).Table 3Summary of cases with serious immune-related adverse events\*.PatientAge (years)SexBMI (kg/m^2^)CancerNo. of CyclesirAEsGradeTreatmentPrognosis120M16.5Hodgkin lymphoma5Pneumonitis3High dose steroidResolutionPembrolizumab resumed255F23.5Vulvar sarcomatoid carcinoma3Pneumonitis5High dose steroidDeath due to pneumonitis362M26.3NSCLC2Pneumonitis3High dose steroidResolutionPembrolizumab discontinued466M26.5NSCLC4Pneumonitis3High dose steroidResoultionSkin rash2AntihistaminePembrolizumab discontinuedPruritis1557M22.9NSCLC2Pneumonitis3High dose steroidResolutionPembrolizumab discontinued657M23.8NSCLC1Pneumonitis3High dose steroidResolutionPembrolizumab discontinued752M27.9NSCLC2Pneumonitis5High dose steroid Mechanical ventilationDeath due to pneumonitis856M21.2NSCLC2Pneumonitis5High dose steroidDeath due to pneumonitis959M20.7NSCLC1Pneumonitis5High dose steroidDeath due to combined infection1051M33.0NSCLC1Hepatitis3High dose steroidImprovementDeath due to respiratory failure1180F22.5Melanoma2Myositis3High dose steroidResolutionMyasthenia gravis4Pyridostigmine IV immunoglobulin Mechanical ventilationPembrolizumab discontinued1260M23.5NSCLC8Skin rash3Topical steroidResolutionPruritis2Low dose steroid AntihistaminePembrolizumab discontinued1364F21.8Bladder cancer1Skin rash3High dose steroid AntihistamineResolution Pembrolizumab resumed1461M33.3NSCLC1Skin rash3AntihistamineResolution Ongoing pembrolizumab therapy\*BMI, body mass index; irAEs, immune-related adverse events; NSCLC, non-small cell lung cancer.^†^Number of cycles of pembrolizumab.

Univariate binary logistic regression analysis was performed to assess risk factors for irAEs (Table [4](#Tab4){ref-type="table"}). A higher BMI was associated with irAEs. If the BMI increases by 1 kg/m^2^, the risk of irAEs increases by 9% (odds ratio \[OR\] = 1.09, 95% confidence interval \[CI\] 1.02--1.17, p = 0.012). The risk of irAEs in melanoma was 2.2 times higher than in lung cancer (OR = 2.22, 95% CI 1.18--4.16, p = 0.013). Among the baseline laboratory data, a dNLR greater than 3 showed a negative correlation with the risk of developing irAEs (OR = 0.31, 95% CI 0.15--0.65, p = 0.002). In addition, the analysis revealed that number of cycles and cumulative dose of pembrolizumab were both risk factors for irAEs (p \< 0.001 for both; Supplementary Fig. [S1](#MOESM1){ref-type="media"}).Table 4Univariate binary logistic regression analysis to determine risk factors for immune- related adverse events\*.Odds ratio95% CI*p*Age0.990.97--1.010.494**Sex**Male1 (Reference)------Female0.810.46--1.410.457BMI1.091.02--1.170.012Underweight l0.580.19--1.750.330Norma1 (Reference)Overweight1.340.70--2.650.357Obese1.640.85--3.180.141**Cancer type**Lung cancer1 (Reference)------Melanoma2.221.18--4.160.013Lymphoma0.990.43--2.310.990Gastric cancer0.370.05--2.920.348Urothelial cancer1.870.36--9.650.458Others0.650.18--2.260.493**Pembrolizumab**Number of cycles1.151.09--1.22\<0.001Cumulative dose1.001.00--1.00\<0.001**Baseline laboratory finding**WBC0.950.89--1.010.102ANC0.940.88--1.010.080dNLR0.8310.71--0.970.016\<31 (Reference)------≥30.310.15--0.650.002Eosinophil counts1.001.00--1.000.639Albumin1.621.01--2.580.043\*CI, confidence interval; BMI, body mass index; WBC, white blood cell counts; ANC, Absolute neutrophil counts; dNLR, derived neutrophil/lymphocyte ratio.

Subsequently, variables included in the final multivariate regression model were selected according to their clinical relevance and statistical significance in a univariate analysis (cutoff: p = 0.20; Table [5](#Tab5){ref-type="table"}). An elevated BMI and multiple cycles of pembrolizumab were associated with higher risk of irAEs in patients treated with pembrolizumab, with an OR of 1.08 (95% CI 1.01--1.16, p = 0.036; Supplementary Fig. [S2](#MOESM1){ref-type="media"}) and 1.15 (95% CI 1.08--1.22, p \< 0.001). We conducted additional analysis by dividing the cycle into two categories with a reference value of 2. When pembrolizumab was administered more than once, the risk of the occurrence of irAEs increased 2.4 times as compared with single dose only (OR 2.44 in multivariate models, 95% CI 1.04--5.70, p = 0.040). In contrast, the risk of irAEs was significantly lower in patients with a baseline dNLR of 3 or more than those with a baseline dNLR less than 3 (OR = 0.37, 95% CI 0.17--0.81, p = 0.012; Supplementary Table [S1](#MOESM1){ref-type="media"} and Supplementary Fig. [S3](#MOESM1){ref-type="media"}).Table 5Multivariate logistic regression analysis of factors associated with immune-related adverse events\*.Odds ratio95% CI*p*BMI1.081.01--1.160.036Number of pembrolizumab cycle1.151.08--1.22\<0.001dNLR ≥ 30.370.17--0.810.012\*Adjusted for sex, age, cancer type, absolute neutrophil counts, and albumin. CI, confidence interval; BMI, body mass index; dNLR, derived neutrophil/lymphocyte ratio.

Discussion {#Sec7}
==========

In this study, we analyzed demographic and lab test data, and data on irAEs occurring in patients treated with pembrolizumab, and identified risk factors associated with these irAEs. We found that the risk of irAEs increased by 9% when BMI increased by 1 kg/m^2^. In addition, patients who received more than one dose of pembrolizumab were at least twice as likely to develop irAEs than those with only one dose. Furthermore, high dNLR at baseline was negatively correlated with risk of irAEs.

The reported incidence of irAEs varies between previous studies, but as many as 80% of patients treated with ICIs experience AEs^[@CR29],[@CR30]^. In our study population, irAEs occurred in 17% of patients. There are several reasons why fewer irAEs have been reported than expected. First, mild AEs that do not require substantive action are unlikely to be recorded in clinical practice. Due to the fact that the data analyzed in this study was collected from retrospective chart review, the incidence of side effects may be lower than other clinical trials where reporting of AEs are more thorough and rigorous. Second, the physicians' lack of awareness of irAEs may have contributed to few reports of rheumatologic AEs such as arthralgia, myalgia, and sicca symptoms. Indeed, suboptimal reporting of irAEs has been demonstrated in a systematic review of clinical trials of ICIs^[@CR23]^. Nevertheless, the clinically meaningful irAEs, especially those requiring intervention, thoroughly included in this study.

The most common irAEs in this study were dermatologic, followed by musculoskeletal, pulmonary, and endocrine disorders. The most common serious irAE was pneumonitis, with higher reported incidence compared to other studies^[@CR24],[@CR30],[@CR31]^. A possible explanation for this result is that the incidence of pneumonitis may have been overestimated due to the fact that other conditions could have been mistaken for pneumonitis, such as infection, and were not filtered into the retrospective chart review.

Recently, predictors of irAEs have been performed mainly on patients with melanoma treated with anti-CTLA-4 antibody ipilimumab. In those studies, an increase in serum interleukin (IL)-17 or an increase in eosinophil count was associated with irAEs^[@CR32],[@CR33]^.

Other studies have shown that immune cell infiltration of bowel mucosa in the early stage of treatment was associated with gastrointestinal toxicity, and that diversification of T-cell repertoire was associated with irAEs^[@CR34],[@CR35]^. Several possible baseline risk factors for irAEs, including personal and family history of autoimmune diseases, tumoral infiltration, opportunistic pathogens, co-medications, and professional exposures, have been proposed, but there is little evidence to support the association of these factors with the development of irAEs^[@CR36]^.

A previous investigation of 84 patients with malignant melanoma treated with ipilimumab showed an increased risk of high-grade AEs in patients with BMI \>25 kg/m^2^ ^[@CR37]^. Consistent with the above finding, the results of the present study also indicated that a higher BMI was associated with an elevated risk for developing irAEs. Possible explanations for these results are that obesity is an inflammatory condition, and may play a role in promoting inflammation involved in the development of irAEs. Leptin, an adipokines secreted by adipocytes, plays a proinflammatory role by stimulating the production of IL-1, IL-6, IL-12, and tumor necrosis factor-α (TNF-α), promoting T cell proliferation, and inhibiting regulatory T cell proliferation^[@CR38]^. Elevated levels of inflammatory cytokines in the sera of patients with irAEs and the improvement of some irAEs with anti-TNF treatment suggest that these cytokines are involved in the development of irAEs^[@CR39],[@CR40]^. Therefore, it is reasonable to speculate that proinflammatory cytokines, which are secreted in association with adipose tissue inflammation, likely promote the development of irAEs.

Neutrophil to lymphocyte ratio (NLR) and dNLR are simple and cost-effective markers that can be obtained using standard blood tests in clinical practice. High NLR is associated with poor outcome in many types of cancer^[@CR41]^. In recent studies of patients with non-small cell lung cancer and malignant melanoma treated with ICIs, pretreatment dNLR greater than 3 was correlated with worse outcomes^[@CR42]--[@CR44]^. These results imply that tumor-induced neutrophil polarization and activation are associated with ICIs treatment failure^[@CR45]^. Our study showed that higher dNLR was linked to lower risk of irAEs. Prior studies have demonstrated that overall and progression-free survival were longer in patients who developed irAEs than those who did not develop irAEs^[@CR46]--[@CR50]^. Considering this positive correlation between irAEs and a response to ICIs, it can be assumed that neutrophils, which are altered in cancer, negatively impact the outcome of cancer immunotherapy or the development of irAEs.

The relationship between the occurrence of irAEs and the number of cycles of pembrolizumab can also be interpreted in the same context. In patients with irAEs, the treatment with ICIs might be more effective in terms of survival, which might lead to continued use of pembrolizumab. Another possibility is that the longer exposure to pembrolizumab increases the risk of developing irAEs. To test these two hypotheses, further investigations taking into account the treatment outcome and the time of occurrence of irAEs are needed.

There are some limitations to our study. First, the study was conducted by retrospective manner, and therefore information bias might have been included. Also, because it was carried out only in one center in South Korea, generalizability could be limited in applying this results to other countries and races. Second, some variables failed to demonstrate statistical significance due to the small number of cases. A multi-center study that include larger number of cases will be useful in confirming the relationship between BMI and irAEs. Third, the outcome of this study did not include assessment of treatment outcomes such as overall survival and progression-free survival. Future research is needed to establish the association of treatment outcome with irAEs and their association with biomarkers. However, previous studies have focused primarily on improved progression-free survival or overall survival in patients with irAEs, so this study has the advantage of identifying risk factors for the occurrence of irAEs.

In conclusion, the risk for irAEs was increased with an elevated BMI and higher number of pembrolizumab cycles. A dNLR greater than 3 was associated with lower risk for irAEs. These results may be useful for predicting and monitoring patients at high risk of developing irAEs. Additional studies are warranted to elucidate the mechanism by which obesity is involved the treatment of ICIs and how the tumor-induced neutrophil polarization affects the cancer immunotherapy.
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